Icon (NASDAQ:ICLR) executives used the company’s latest earnings call to address the results of an accounting investigation, outline fourth-quarter and full-year 2025 performance, and provide guidance...
Highlights Quarter four revenue was $2,112.5 million. Full year revenue was $8,251 million. Quarter four adjusted...
Barchart Research What to Expect from ICLR Earnings ICLR Generated May 26, 2026 Current Price $113.85 EPS Estimate $$2.80 Consensus Rating Moderate Buy Average Move 9.83% ICON's First Post-Investigation...
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market...
Barchart Research What to Expect from ICLR Earnings ICLR Generated May 19, 2026 Current Price $113.55 EPS Estimate $$2.80 Consensus Rating Moderate Buy Average Move 8.86% Icon's Accounting Investigation...
New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas...
Barchart Research What to Expect from ICLR Earnings ICLR Generated May 12, 2026 Current Price $121.94 EPS Estimate $$2.80 Consensus Rating Moderate Buy Average Move 8.86% Icon's Delayed Earnings Will Reveal...
Barchart Research What to Expect from ICLR Earnings ICLR Generated May 5, 2026 Current Price $121.32 EPS Estimate $$2.80 Consensus Rating Moderate Buy Average Move 8.86% Icon Plc Reports Earnings After...
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company’s...